India makes quality check at government labs mandatory for cough syrup exports after overseas death

India makes quality check at government labs mandatory for cough syrup exports after overseas death

According to a notification from the Directorate General of Foreign Trade, the new regulation will be applicable from June 1.

FPJ Web DeskUpdated: Tuesday, May 23, 2023, 12:14 PM IST
article-image
India makes quality check at government labs mandatory for cough syrup exports after overseas death | File

Cough Syrup manufacturers will have to get samples tested and cleared by the government-certified laboratories before they can be exported overseas from June 1, announced the Directorate General of Foreign Trade on Monday. This decision comes after quality concerns were raised globally for India-made cough syrups that were linked to dozens of deaths in Gambia and Uzbekistan last year.

The notification by the DGFT said, "Cough Syrup shall be permitted to be exported subject to the export sample being tested and production of the Certificate of Analysis issued by any of the laboratories," as mentioned in the notification.

What labs are approved by the Centre?

The specified central government labs include National Accreditation Board for Testing and Calibration Laboratories, Indian Pharmacopoeia Commission, central drugs lab in Kolkata, regional testing lab in Chandigarh and Guwahati and central drug testing lab in Chennai, Mumbai and Hyderabad.

The Ministry of Health and Family Welfare would work with the exporters in order to ensure smooth implementation of this new notification.

Notification from DGFT

Notification from DGFT |

Pharmaceutical industry under duress due to deaths abroad

India's pharmaceutical industry that was valued at $41 billion experienced a major setback after Indian cough syrup was connected with the death of close to 70 children in Gambia and 18 in Uzbekistan.

In the last fiscal the exports of cough syrup was at $17.6 billion which was higher than the exports in the 2021-22.

RECENT STORIES

RBI May Go For 25 Bps Rate Cut As Inflation Likely To Remain Benign: SBI Research Report

RBI May Go For 25 Bps Rate Cut As Inflation Likely To Remain Benign: SBI Research Report

PayNearby Plans IPO In FY26, To Finalise Merchant Banker Soon After ₹300 Crore FY25 Revenue

PayNearby Plans IPO In FY26, To Finalise Merchant Banker Soon After ₹300 Crore FY25 Revenue

Suba Hotels Raises Over ₹21 Crore From Anchor Investors; IPO To Open On September 29

Suba Hotels Raises Over ₹21 Crore From Anchor Investors; IPO To Open On September 29

Now Your Dream Car Is Within Reach, Banks Slash Loan Rates Starting At Just 7.6%

Now Your Dream Car Is Within Reach, Banks Slash Loan Rates Starting At Just 7.6%

Indian Drug Makers Largely Shielded From US Tariff On Patented Medicines; Sun Pharma Most Exposed

Indian Drug Makers Largely Shielded From US Tariff On Patented Medicines; Sun Pharma Most Exposed